about
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancerThe 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesAndrogen receptor variants occur frequently in castration resistant prostate cancer metastasesNovel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancerMelanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interactionAndrogen receptor molecular biology and potential targets in prostate cancerNew strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathwayRole of desumoylation in the development of prostate cancerA Perspective of Immunotherapy for Prostate CancerMechanisms of resistance in castration-resistant prostate cancer (CRPC)New drugs for prostate cancerAbiraterone in the treatment of metastatic castration-resistant prostate cancerIntraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancerBeyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationAndrogens and prostate diseaseModulation of Androgen Receptor Activation Function 2 by Testosterone and DihydrotestosteroneIntraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.Targeting intratumoral androgens: statins and beyondThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceTAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domainsAn androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP)Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironmentCYP17 inhibitors for prostate cancer therapyThe aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cellsAbiraterone and increased survival in metastatic prostate cancerMultimodal imaging guided preclinical trials of vascular targeting in prostate cancer.Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionAR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas.Exosomes in prostate cancer: putting together the pieces of a puzzle.Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effectsAtmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer.A role for the androgen-receptor in clinically localized and advanced prostate cancer.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
P2860
Q21202034-37095BC0-90C5-40A4-AE08-58B7D6A24D76Q21285041-C0A38290-C010-4C53-B8E0-919A194111FAQ21558502-A7ED54FC-0E32-46B2-99D4-844E7360DBE8Q24299807-08309B37-E37E-4724-ADB0-B1C4B25A9D7EQ24556963-013CA171-FE8F-4922-96D2-21C1C6239AEEQ24602861-F1F1AF79-2EB1-4F30-AC64-FC52E5E63DBDQ24603649-975D35C9-4DC6-4219-BC33-8F29DFE44741Q24676101-BFD68534-97C2-4A45-AAC7-7A9AF1A7597FQ26741277-EA03EF52-770C-47DC-9AD7-7912EAC3895EQ26774221-DF951EF4-2805-49B0-BFAB-E5E2A6FBC69FQ26827515-8BF6FEC9-1A4D-4147-AF81-7DB037EB7682Q26853635-9E4D4D22-B21E-4D72-BD41-AE436F3FCABFQ27005840-DB6B71D8-EE66-44CF-8F67-86351888A561Q27007208-B6049AFA-EF8E-4108-9600-E7ADA4519698Q27010093-568A1913-38C5-4582-84EA-5866BFC4E30EQ27646416-56EE90E0-5E29-42AF-9621-7ED3B3ECAFFEQ27690719-76FFAA69-356F-4D8A-A669-5901AD447A2DQ28073619-9D00A720-2AD7-4C5E-A27A-943384AAA896Q28076745-BA29850C-85DD-4D10-8108-3879120A5633Q28119073-97329A41-5430-4103-8D0B-4EAE29BEEDB9Q28258333-132EEAF1-3C1C-4800-B2F0-C583DAA56023Q28278828-9F9CAF98-C93C-4852-8BAB-182C86604960Q28298818-7081134E-AEE8-4EBD-BA70-A2EEB40C0B2EQ28538111-6F80B038-F19C-4639-B3A4-E9025FC56EC4Q29617512-0B4E6DD5-811B-412A-81EF-4557B5BABF3EQ30393012-87C229A9-CB8C-4074-8198-911D69059469Q30409623-9025FDB8-87E8-4359-A642-1A2F784E86C2Q30436959-E0C5D76C-233D-44E9-BBD9-E55316A8982DQ30495758-5DCEF455-FCB2-4683-94EC-A72033232FEDQ30499412-B37AF9D3-8DE9-441F-880F-9C7023464B79Q30513836-0C90F989-BE57-44A8-B225-DCEAB49E6850Q30544584-318E2FB2-3E4F-4AEB-AD81-B525B9DD6128Q33302103-8163518F-6FE8-4F1F-82F6-C36083BA7FF6Q33357387-143785A3-72EA-4DC8-8A3D-7C15F9867E84Q33382106-744749E0-68A4-4421-AD0D-97A37C71D7B1Q33446864-F85E4C50-A851-4365-85EE-798612AE3143Q33561073-FDAC8C4C-4714-424B-A834-CE0389A18BD2Q33566395-09D1142C-6787-4ED3-8216-010949F2E2BBQ33590201-B9511642-57E9-4573-A54A-3A64936F4A09Q33770374-566728E9-44D1-4F80-8BE6-B2F3DF82EB46
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The androgen axis in recurrent prostate cancer.
@en
The androgen axis in recurrent prostate cancer.
@nl
type
label
The androgen axis in recurrent prostate cancer.
@en
The androgen axis in recurrent prostate cancer.
@nl
prefLabel
The androgen axis in recurrent prostate cancer.
@en
The androgen axis in recurrent prostate cancer.
@nl
P2093
P1476
The androgen axis in recurrent prostate cancer.
@en
P2093
Catharina M Weaver
Christopher W Gregory
Elizabeth M Wilson
Frank S French
James L Mohler
O Harris Ford
Peter Petrusz
P304
P356
10.1158/1078-0432.CCR-1146-03
P407
P577
2004-01-01T00:00:00Z